Suggestions
Jeff Bird
Managing Director at Bluebird Ventures
Jeff Bird is a Venture Capital investor specializing in early-stage Life Science companies. With a background as a private company CEO and over a decade of experience at Gilead Sciences, Jeff holds an MD and Ph.D. from Stanford University.
Jeff Bird's educational journey includes pursuing a Medical Degree (MD) in Medicine and a Ph.D. in Cancer Biology from Stanford University School of Medicine. He also completed his Bachelor of Science (BS) at Stanford University.
Throughout his career, Jeff Bird has been associated with several renowned organizations. He served as a Board Member at Stanford Health Care and was an investor at Leyden Labs, Sutter Hill Ventures, Foresight Dx, Kriya Therapeutics, Nutcracker Therapeutics, Epirium, Bluebird Ventures, Procyrion, Inc., GRAIL, Inc., Helix, Teneobio, Inc., Forty Seven, Inc., and Portola Pharmaceuticals. Furthermore, he held managerial positions at Sutter Hill Ventures and Illumina, and was the CEO of Verinata Health, Inc. Jeff's tenure at Gilead Sciences included roles such as Senior Vice President of Business Operations, VP of Corporate Development, and Director of Scientific Programs.
